Intravenous Immunoglobulin (IVIG) Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Apr 2018| TMR518A| Transparency

Report Highlights

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Humoral Immunodeficiency
Idiopathic Thrombocytopenic Purpura (ITP)
Guillain-Barre Syndrome
Myasthenia Gravis
Multifocal Motor Neuropathy (MMN)
Kawasaki Disease
Hypogammaglobulinemia
Chronic Lymphocytic Leukemia
Others
Global Intravenous immunoglobulin (IVIG) Market, by End-user

Hospitals
Clinics
Home Care
Global Intravenous immunoglobulin (IVIG) Market, by Geography

North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
Australia
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
Saudi Arabia
Rest of Middle East & Africa

  • Table 1 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 2 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
  • Table 3 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2016–2024
  • Table 4 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 5 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
  • Table 6 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 7 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 8 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
  • Table 9 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 10 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
  • Table 11 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
  • Table 12 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
  • Table 13 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2014–2024
  • Table 14 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
  • Table 15 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024
  • Table 16 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2014–2024
  • Table 17 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
  • Table 18 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024
  • Figure 1 : Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 2 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 3 : Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2014–2024
  • Figure 4 : Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2014–2024
  • Figure 5 : Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2014–2024
  • Figure 6 : Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2014–2024
  • Figure 7 : Global Myasthenia Gravis Market Revenue, US$ Mn, 2014–2024
  • Figure 8 : Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2014–2024
  • Figure 9 : Global Kawasaki Disease Market Revenue, US$ Mn, 2014–2024
  • Figure 10 : Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2014–2024
  • Figure 11 : Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2014–2024
  • Figure 12 : Global Other Indications Market Revenue, US$ Mn, 2014–2024
  • Figure 13 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
  • Figure 14 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 15 : Global Hospitals Market Revenue, US$ Mn,
  • Figure 16 : Global Clinics Market Revenue, US$ Mn,
  • Figure 17 : Global home care Market Revenue, US$ Mn, 2014–2024
  • Figure 18 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
  • Figure 19 : Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2016 and 2024
  • Figure 20 : Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
  • Figure 21 : North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
  • Figure 22 : North America Market Attractiveness Analysis, by Country
  • Figure 23 : North America Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 24 : North America Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 25 : North America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 26 : North America Market Attractiveness Analysis, by Indication
  • Figure 27 : North America Market Attractiveness Analysis, by End-user
  • Figure 28 : Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
  • Figure 29 : Europe Market Attractiveness Analysis, by Country
  • Figure 30 : Europe Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 31 : Europe Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 32 : Europe Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 33 : Europe Market Attractiveness Analysis, by Indication
  • Figure 34 : Europe Market Attractiveness Analysis, by End-user
  • Figure 35 : Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 36 : Asia Pacific Market Attractiveness Analysis, by Country
  • Figure 37 : Asia Pacific Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 38 : Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 39 : Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 40 : Asia Pacific Market Attractiveness Analysis, by Indication
  • Figure 41 : Asia Pacific Market Attractiveness Analysis, by End-user
  • Figure 42 : Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 43 : Latin America Market Attractiveness Analysis, by Country
  • Figure 44 : Latin America Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 45 : Latin America Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 46 : Latin America Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 47 : Latin America Market Attractiveness Analysis, by Indication
  • Figure 48 : Latin America Market Attractiveness Analysis, by End-user
  • Figure 49 : Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
  • Figure 50 : Middle East & Africa Market Attractiveness Analysis, by Country
  • Figure 51 : Middle East & Africa Market Value Share Analysis, by Indication, 2016 and 2024
  • Figure 52 : Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
  • Figure 53 : Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
  • Figure 54 : Middle East & Africa Market Attractiveness Analysis, by Indication
  • Figure 55 : Middle East & Africa Market Attractiveness Analysis, by End-user
  • Figure 56 : Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us